Antiangiogenesis: biology and utility in the treatment of gliomas

References

• Lakka SS, Rao JS. Anti-angiogenic therapy in brain tumors. Expert Rev. Neurother.8(10), 1457–1473 (2008).
   PubMedGoogle Scholar
• Bergers G, Benjamin L. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer3(6), 401–410 (2003).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell86(3), 353–364 (1996).
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N. Engl. J. Med.358(19), 2039–2044 (2008).
   PubMed Web of Science ®Google Scholar
• Semenza GL. A new weapon for attaching tumor blood vessels. N. Engl. J. Med.358(19), 2066–2067 (2008).
   PubMed Web of Science ®Google Scholar
• Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science319, 195–198 (2008).
   PubMed Web of Science ®Google Scholar
• Nolan DJ, Ciarrocchi A, Mellick AS et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev.21, 1546–1558 (2007).
   PubMed Web of Science ®Google Scholar
• Peters BA, Diaz LA, Polyak K et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat. Med.11, 261–262 (2005).
   PubMed Web of Science ®Google Scholar
• Rajantie I, Ilmonen M, Alminaite A et al. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood104(7), 2084–2086 (2004).
   PubMed Web of Science ®Google Scholar
• Santarelli JG, Udani V, Yung CY et al. Preuss Resident Research Award: bone marrow-derived Flk-1-expressing CD34+ cells contribute to the endothelium of tumor vessels in mouse brain. Clin. Neurosurg.52, 384–388 (2005).
   PubMedGoogle Scholar
• Leenders WP, Küsters B, Verrijp K et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin. Cancer Res.10, 6222–6230 (2004).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med.9(6), 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• Kowanerz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res.12(17), 5018–5022 (2006).
   PubMed Web of Science ®Google Scholar
• Fischer I, Gagner JP, Law M et al. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol.15(4), 297–310 (2005).
   PubMed Web of Science ®Google Scholar
• Kargiotis O, Rao JS, Kyritsis AP. Mechanisms of angiogenesis in gliomas. J. Neurooncol.78(3), 281–293 (2006).
   PubMed Web of Science ®Google Scholar
• Lamszus K, Heese O, Westphal M. Angiogenesis-related growth factors in brain tumors. Cancer Treat. Res.117, 169–190 (2004).
   PubMedGoogle Scholar
• Plate KH, Risau W. Angiogenesis in malignant gliomas. Glia15(3), 339–347 (1995).
   PubMed Web of Science ®Google Scholar
• Jain RK. Normaliziing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med.7(9), 987–989 (2001).
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science307(5706), 58–62 (2005).
   PubMed Web of Science ®Google Scholar
• Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-oncology7(2), 134–153 (2005).
   PubMed Web of Science ®Google Scholar
• Kaur B, Tan C, Brat DJ et al. Genetic and hypoxic regulation of angiogenesis in gliomas. J. Neurooncol.70(2), 229–243 (2004).
   PubMed Web of Science ®Google Scholar
• Tong RT, Boucher Y, Kozin SV et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res.64(11), 3731–3736 (2004).
   PubMed Web of Science ®Google Scholar
• Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature437, 497–504 (2005).
   PubMed Web of Science ®Google Scholar
• Ferrara N. VEGF as a therapeutic target in cancer. Oncology69(Suppl. 3), 11–16 (2005).
   PubMed Web of Science ®Google Scholar
• Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol.3(1), 24–40 (2006).
   PubMedGoogle Scholar
• Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science312(5777), 1171–1175 (2006).
   PubMed Web of Science ®Google Scholar
• Chi A, Norden AD, Wen PY. Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev. Anticancer Ther.7(11), 1537–1560 (2007).
   PubMed Web of Science ®Google Scholar
• Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol.21(8), 1624–1636 (2003).
   PubMed Web of Science ®Google Scholar
• Lamszus K, Kunkel P, Westphal M. Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir.88(Suppl.), 169–177 (2003).
   Google Scholar
• Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat. Rev. Cancer3(7), 489–501 (2003).
   PubMed Web of Science ®Google Scholar
• Salhia B, Tran NL, Symons M, Winkles JA, Jutka JT, Berens ME. Molecular pathways triggering glioma cell invasion. Expert Rev. Mol. Diagn.6(4), 613–626 (2006).
   PubMed Web of Science ®Google Scholar
• Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin. Oncol.23(10), 2411–2422 (2005).
   PubMed Web of Science ®Google Scholar
• Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-oncology7(4), 436–451 (2005).
   PubMed Web of Science ®Google Scholar
• Kunkel P, Ulbricht U, Bohlen P et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res.61(18), 6624–6628 (2001).
   PubMed Web of Science ®Google Scholar
• Plate KH, Breier G, Millaauer B et al. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res.53(23), 5822–5827 (1993).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin. Biol. Ther.8(4), 541–553 (2008).
   PubMed Web of Science ®Google Scholar
• Samoto K, Ikezaki K, Ono M et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res.55(5), 1189–1193 (1995).
   PubMed Web of Science ®Google Scholar
• Stefanik DF, Fellows WK, Rizkalla LR et al. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J. Neurooncol.55, 91–100 (2001).
   PubMed Web of Science ®Google Scholar
• Stefanik DF, Rizkalla LR, Soi A et al. Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. Cancer Res.51(20), 5760–5765 (1991).
   PubMed Web of Science ®Google Scholar
• Winkler F, Kozin SV, Tong R et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation angiopoietin-1 and matrix metalloproteinases. Cancer Cell6, 553–563 (2004).
   PubMed Web of Science ®Google Scholar
• Zagzag D, Zhong H, Scalzitti JM et al. Expression of hypoxia-inducible factor 1α in brain tumors: association with angiogenesis, invasion, and progression. Cancer88(11), 2606–2618 (2000).
   PubMed Web of Science ®Google Scholar
• Zheng PP, Hop WC, Luider TM et al. Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas. Ann. Neurol.62, 40–48 (2007).
   PubMed Web of Science ®Google Scholar
• Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology66(8), 1258–1260 (2006).
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res.13, 1253–1259 (2007).
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol.25(30), 4722–4729 (2007).
   PubMed Web of Science ®Google Scholar
• Chen C, Silverman DHS, Geist C et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol.25(30), 4714–4721 (2007).
   PubMed Web of Science ®Google Scholar
• Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant glioma: efficacy, toxicity and patterns of recurrence. Neurology70, 779–787 (2008).
   PubMed Web of Science ®Google Scholar
• Cloughsey TF, Prados MD, Mikkelsen T et al. A Phase II randomized non-comparative trial of bevacizumab alone or in combination with irinotecan on 6-month progression free survival in recurrent treatment refractory glioblastoma. J. Clin. Oncol.26(Suppl. 15), 91 (2008).
   Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, diTomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11, 83–95 (2007).
   PubMed Web of Science ®Google Scholar
• Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med.358(11), 1129–1136 (2008).
   PubMed Web of Science ®Google Scholar
• Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors: a review. Eur. J. Cancer42, 3127–3139 (2006).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Scelzi E, Salmistraro G et al. Incidence of risk of thromboembolism during treatment of high-grade gliomas: a prospective study. Eur. J. Cancer33, 1592–1596 (1997).
   PubMed Web of Science ®Google Scholar
• Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer89, 640–646 (2000).
   PubMed Web of Science ®Google Scholar
• Semrad TJ, O’Donnell R, Wun T et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J. Neurosurg.l06(4), 601–608 (2007).
   Google Scholar
• Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol.7(3), 369 (2005) (Abstract).
   Web of Science ®Google Scholar